{"filings":[{"id":746477,"accession_number":"0001628280-26-039147","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-05-29T20:05:00+00:00","items":["5.02"],"status":"ready","headline":"Director Anne O'Riordan not standing for re-election at Jazz's 2026 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Class III director Anne O'Riordan will not seek re-election at the 2026 annual meeting, continuing board refreshment.","O'Riordan's decision was not due to any dispute or disagreement with the company or board.","Board will continue to evaluate composition; no immediate replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91772,"accession_number":"0001232524-26-000024","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q1 revenue $1.1B (+19% YoY), EPS $4.43 GAAP / $6.34 adj; Zanidatamab PDUFA Aug 25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.1B (+19% YoY); GAAP EPS $4.43, non-GAAP adj. EPS $6.34; operating cash flow $408M.","Xywav net product sales $408M (+18% YoY) with 425 net patient adds; Epidiolex grew 15% YoY.","Zanidatamab sBLA for HER2+ 1L GEA granted Priority Review; PDUFA date Aug 25, 2026.","Company reaffirms 2026 revenue and expense guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":4.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1068900000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102091,"accession_number":"0001232524-26-000012","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma FY2025 revenue $4.3B (+5% YoY); GAAP net loss $356M vs $560M income in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues record $4.3B in FY2025 (+5% YoY); Q4 revenue $1.2B (+10% YoY).","GAAP net loss $356M ($5.84 diluted loss per share) vs prior year income of $560M ($8.65 EPS).","Non-GAAP adjusted net income $522M ($8.38 EPS) vs $1.35B ($20.65 EPS) in 2024; adjusted down significantly.","Xywav $1.7B (+12%), Epidiolex $1.1B (+9%) in 2025; Modeyso launch generated $48M.","2026 revenue guidance $4.25-$4.50B; sBLA submission for zanidatamab in GEA expected in 1Q26."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":4267586000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102090,"accession_number":"0001193125-26-009899","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reaffirms FY2025 total revenue guidance at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Expects to meet previously announced total revenue guidance range for FY2025 year ended Dec 31, 2025.","Provided revenue expectations for Xywav, Epidiolex, and Modeyso for the full year 2025.","Presentation delivered at 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118425,"accession_number":"0001193125-25-283887","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Positive Phase 3 results for Ziihera: significant PFS/OS improvement in first-line HER2+ GEA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS clinically meaningful trend at first interim analysis.","Ziihera + tislelizumab + chemo showed statistically significant OS and PFS improvements vs control.","Benefit observed in both PD-L1 positive and negative subgroups; improvements in ORR and DoR.","Company plans to submit sBLA in first half of 2026; data to be presented at medical meeting Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118424,"accession_number":"0001232524-25-000073","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma Q3 rev $1.13B (+7%), GAAP EPS $4.08, adj. EPS $8.13; FY25 rev guid narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.126B (+7% YoY); GAAP net income $251M, non-GAAP adj. net income $501M.","Epidiolex sales grew 20% to $302.6M; Xywav sales grew 11% to $431.4M; Modeyso launch contributed $11.0M.","Zepzelca + atezolizumab combo approved for 1L maintenance ES-SCLC; NCCN inclusion.","Saniona licensing agreement for SAN2355, a Kv7.2/7.3 activator for epilepsy and other indications.","FY2025 total revenue guidance narrowed to $4.175-$4.275B from $4.150-$4.300B."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3069660000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118423,"accession_number":"0001628280-25-046763","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz Pharma appoints Dr. Ted Love to board; director Kenneth O'Keefe to retire Dec 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Ted Love appointed as Class I director effective Dec 1, 2025, term expiring at 2027 AGM.","Love will serve on Audit and Science & Medicine Committees under standard non-employee director compensation.","Director Kenneth O'Keefe retires from Board effective Dec 1, 2025, with no dispute or disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118422,"accession_number":"0001193125-25-245815","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz settles patent litigation with Avadel; grants Lumryz license, pays $90M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jazz pays $90M lump sum to Avadel and waives certain prior royalties to settle all litigation.","Avadel gets immediate license for Lumryz in narcolepsy; license for other indications starts March 1, 2028.","Avadel will pay 3.85% royalty on narcolepsy Lumryz sales (starting Oct 1, 2025) and 10% on other indications.","Jazz expects ~$90M pre-tax charge in Q3 2025, funded with cash on hand.","Jazz denies all alleged wrongdoing; both parties dismiss pending legal proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134860,"accession_number":"0001232524-25-000061","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q2 GAAP net loss $718M; revenue $1.05B up 2%; updates FY25 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $1.05B, up 2% YoY; GAAP net loss $718.5M vs $168.6M profit in Q2 2024.","Non-GAAP adjusted net loss $504.8M vs $360.7M income; FY2025 revenue guidance revised to $4.15-$4.30B.","Xywav revenue +13% to $415.3M; added ~625 net patients in Q2, active patients ~15,225.","Renee Gala named President and CEO effective Aug 11; Bruce Cozadd becomes Chairman.","FDA Priority Review for Zepzelca combo in 1L ES-SCLC (PDUFA Oct 7); dordaviprone PDUFA Aug 18."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1943553000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134859,"accession_number":"0001232524-25-000051","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jazz Pharma shareholders elect four directors and ratify KPMG as auditor at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four director nominees were elected: Cook, Enright, Mulligan, Riedel, each with >46M votes for.","KPMG ratified as independent auditor for FY2025 with 54.8M for, 0.99M against (no broker non-votes).","Say-on-pay advisory vote approved: 48.3M for, 2.9M against, 193,593 abstentions.","Board granted authority to issue ordinary shares for cash without pre-emption rights: 53.6M for, 2.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134858,"accession_number":"0001193125-25-157388","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.","Bruce Cozadd retires as CEO on Aug 11, transitions to advisor through Sep 12, then remains Chairperson.","Gala's base salary increases to $1.2M (from $900k); target bonus rises to 110% of salary (from 80%).","Gala receives a one-time promotion equity grant of ~$6.5M (33% RSUs, 67% PSUs) on top of $6M annual grant.","Severance enhanced: lump sum of 150% base salary (was 100%) and COBRA coverage extended to 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151797,"accession_number":"0001232524-25-000025","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).","Xywav revenue $344.8M (+9% YoY), Epidiolex $217.7M (+10% YoY); Xyrem fell 42% to $37.2M.","Affirmed 2025 total revenue guidance $4.15-4.40B; updated to reflect Chimerix acquisition and Xyrem settlements.","Completed Chimerix acquisition in April; added dordaviprone; PDUFA Aug 18, 2025 for recurrent H3 K27M-mutant glioma.","Submitted sNDA for Zepzelca in 1L ES-SCLC maintenance; positive CHMP opinion for zanidatamab in 2L BTC."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":897841000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151796,"accession_number":"0001193125-25-087233","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jazz completes $935M acquisition of Chimerix, adds dordaviprone to pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition completed for ~$935M cash; $8.55 per share.","Dordaviprone for H3 K27M-mutant diffuse glioma under FDA Priority Review; PDUFA date Aug 18, 2025.","If approved, could be first FDA-approved therapy for that indication; potential near-term opportunity.","Also in Phase 3 ACTION trial for newly diagnosed, non-recurrent diffuse glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151795,"accession_number":"0001193125-25-075871","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Jazz Pharma to pay $145M to settle Xyrem antitrust class action; records Q1 charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jazz Pharmaceuticals Ireland subsidiary agrees to pay $145M lump sum to settle indirect Xyrem purchaser class action.","Company will record a pre-tax charge of approximately $145M in Q1 2025, funded by cash on hand.","Settlement remains subject to court approval; Jazz denies all alleged wrongdoing.","The settlement resolves the majority of claims in the multi-district litigation; additional settlements with remaining plaintiffs may be significant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170661,"accession_number":"0001193125-25-046226","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.","Chimerix's dordaviprone (NDA under Priority Review, PDUFA Aug 18, 2025) targets H3 K27M-mutant diffuse glioma.","If approved, dordaviprone could be first FDA-approved therapy for this rare brain tumor; eligible for Rare Pediatric Disease PRV.","Jazz expects to fund deal from existing cash; transaction projected to close in Q2 2025.","Chimerix board unanimously recommends shareholders tender shares; patent protection into 2037 with potential extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.88,"calibrated_materiality_score":0.88,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170658,"accession_number":"0001193125-25-047189","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K/A","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals to acquire Chimerix for $8.55/share in all-cash tender offer","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer to commence by March 24, 2025; Chimerix board unanimously recommends.","Offer subject to minimum tender condition, HSR clearance, and no material adverse effect.","After tender, merger under DGCL Section 251(h); remaining shares converted at same $8.55.","Amendment No. 1 corrects typographical error in exhibit; no substantive changes to terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170660,"accession_number":"0001232524-25-000009","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma reports record 2024 revenue $4.1B; guides 2025 rev $4.15-4.40B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue $4.07B for FY2024, up 6% YoY; Q4 revenue $1.09B, up 8% YoY.","GAAP diluted EPS $8.65 (FY2024) vs $6.10 (FY2023); Non-GAAP diluted EPS $20.90 vs $18.29.","Xywav+Epidiolex grew 16% and 15% YoY; oncology revenue surpassed $1.1B (+9%).","2025 guidance: total revenue $4.15-4.40B; GAAP EPS $9.15-11.50; Non-GAAP EPS $22.50-24.00.","Cash from ops $1.4B; voluntary $750M debt prepayment in Jan 2025; Ziihera launch initial sales $1.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":8.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":4068950000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170659,"accession_number":"0001193125-25-004989","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Pharma confirms FY2024 revenue guidance met at J.P. Morgan conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company expects to meet previously announced total, neuroscience and oncology revenue guidance for year ended Dec 31, 2024.","Outlook disclosed at J.P. Morgan Healthcare Conference on Jan 14, 2025.","No specific revenue or EPS figures provided; guidance ranges unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187640,"accession_number":"0001193125-24-279656","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jazz CEO Bruce Cozadd to retire by end of 2025; company to search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Cozadd notified Board of intent to retire as CEO upon appointment of successor.","Formal search process will consider both internal and external candidates for CEO.","After retiring as CEO, Cozadd will continue to serve as Chairperson of the Board.","Cozadd remains CEO until successor is appointed; transition expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187639,"accession_number":"0001193125-24-266184","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals expands revolver to $885M, extends maturity to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving credit facility increased from $500M to $885M; maturity extended from May 2026 to Nov 2029.","Initial applicable margin reduced by 125 bps: Term SOFR +2.00% and prime +1.00%.","Facility was undrawn as of Nov 26, 2024; financial covenants apply only when drawn.","Springing maturity provisions tied to 2026 exchangeable notes and 2028 term loan thresholds.","Amendment adds new lenders and commits to customary conditions for effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187638,"accession_number":"0001193125-24-262940","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jazz Pharmaceuticals receives FDA accelerated approval for Ziihera in HER2+ biliary tract cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Ziihera (zanidatamab-hrii) for adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.","Approval based on 52% objective response rate and median duration of response of 14.9 months by independent central review.","First and only dual HER2-targeted bispecific antibody approved for this indication in the U.S.","Continued approval contingent on confirmatory Phase 3 trial HERIZON-BTC-302; Boxed Warning for embryo-fetal toxicity.","Investor webcast scheduled for December 11, 2024, to discuss clinical data and commercialization strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187637,"accession_number":"0001232524-24-000084","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q3 revenue tops $1.05B, raises EPS guidance, affirms 2024 revenue outlook at $4.0-4.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 record revenue >$1.05B; key growth drivers (Xywav, Epidiolex, Rylaze) up 14% YoY.","Total 2024 revenue guidance reaffirmed at $4.0-4.1B; oncology revenue guidance lowered to $1.08-1.13B.","GAAP EPS guidance raised to $6.70-8.50; non-GAAP EPS guidance raised to $19.50-20.60.","Xywav added ~400 net patients in Q3; strong sleep performance continues.","Zanidatamab PDUFA Nov 29 for 2L BTC; sNDA for Zepzelca in 1L ES-SCLC planned 1H25."],"consensus_eps_estimate":null,"consensus_eps_actual":5.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":2980777000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187636,"accession_number":"0001232524-24-000073","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Jazz Pharma ends Palo Alto lease early, signs new lease nearby","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Existing lease at 3170 Porter Drive terminated effective June 30, 2025 (original expiry Oct 2029).","Landlord secured replacement tenant; Jazz will pay a lease modification payment.","New lease executed Oct 11, 2024 for 3000 El Camino Real, Palo Alto; occupancy by July 1, 2025.","Jazz continues U.S. operations in Palo Alto, Carlsbad, CA and Philadelphia, PA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204123,"accession_number":"0001193125-24-215168","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Jazz Prices $1B 3.125% Exchangeable Notes Due 2030, Preps $500M Loan Repayment & $150M Buyback","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.0B aggregate principal of 3.125% exchangeable senior notes due 2030, including $150M overallotment exercised.","Initial exchange price ~$153.05 per share, a ~40% premium over Sept 3 closing price of $109.32.","Net proceeds ~$981M; ~$500M to prepay term loans under credit agreement, remainder for general corporate.","Concurrent $150M share repurchase from note purchasers at $109.32/share, reducing remaining buyback authority.","Transaction closed Sept 6, 2024; notes guaranteed by Jazz on senior unsecured basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204122,"accession_number":"0001193125-24-208688","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.","Injunction prevents Avadel from seeking FDA approval or marketing Lumryz for idiopathic hypersomnia or other new indications.","Avadel is enjoined from infringing Claim 24 of Jazz's '782 patent through February 2036, except for narcolepsy and existing patients.","Court awarded Jazz an ongoing royalty for future narcolepsy Lumryz sales at a rate to be determined above 3.5%.","Jazz previously won jury verdict finding '782 patent valid and damages for past Lumryz sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204121,"accession_number":"0001232524-24-000065","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.","Zanidatamab granted Priority Review; PDUFA Nov 29, 2024 for 2L BTC.","Narrowed 2024 total revenue guidance to $4.0-$4.1B; lowered oncology outlook to $1.10-$1.15B.","GAAP EPS guidance raised to $6.00-$8.00; non-GAAP EPS to $19.20-$20.30.","GAAP net income affirmed $385-$530M; non-GAAP adjusted net income $1.275-$1.350B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":1925808000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204120,"accession_number":"0001232524-24-000056","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jazz Pharma shareholders elect directors, ratify auditor, approve say-on-pay at 2024 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected (Hamill, Kennedy, O'Keefe, Smith) with 50.5M-52.8M votes for.","Ratification of KPMG as auditor for FY2024 approved (56.7M for, 1.2M against).","Advisory say-on-pay passed (49.3M for, 4.8M against); one-year frequency preferred (52.7M).","Authority to issue ordinary shares for cash without pre-emption rights approved (52.6M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204119,"accession_number":"0001193125-24-181938","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Jazz reprices $2.7B term loan; margin cut 75 bps to 2.25%+SOFR","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Amendment No. 2 to Credit Agreement; Tranche B-2 Dollar Term Loans replace Tranche B-1 at same $2,707,000,000 outstanding.","Interest margin reduced 75 basis points: new rates are 2.25% (Term SOFR) and 1.25% (prime) vs prior margins.","Maturity unchanged at May 5, 2028; quarterly amortization of 0.2863% of initial principal; SOFR floor of 0.50% remains.","Proceeds from new $289.6M additional borrowing used to repay non-converted Tranche B-1 loans; structure includes converting and non-converting lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220844,"accession_number":"0001193125-24-151941","cik":1232524,"company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Catherine Sohn to retire, not standing for re-election at 2024 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Catherine Sohn, Pharm.D. notified board of retirement effective at 2024 annual general meeting.","Decision not due to any dispute or disagreement with company or board on operations, policies, or practices.","No replacement or nominee announced for the departing director position."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14785659269.717165,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}